Privia Health Group (NASDAQ:PRVA) Director Sells $194,622.12 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 7,788 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $24.99, for a total transaction of $194,622.12. Following the sale, the director directly owned 68,188 shares of the company’s stock, valued at $1,704,018.12. This represents a 10.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, February 27th, Matthew Shawn Morris sold 16,550 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $413,750.00.
• On Friday, December 12th, Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock. The stock was sold at an average price of $25.01, for a total transaction of $341,311.47.

Privia Health Group Trading Up 2.2%

NASDAQ PRVA opened at $24.30 on Thursday. The firm’s 50 day simple moving average is $23.07 and its 200 day simple moving average is $23.54. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 142.94, a P/E/G ratio of 1.59 and a beta of 0.82. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $26.51.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the prior year, the company earned $0.21 earnings per share. The company’s quarterly revenue was up 17.4% on a year-over-year basis. On average, equities research analysts forecast that Privia Health Group, Inc. will post 0.14 earnings per share for the current year.

Hedge Funds Weigh In On Privia Health Group

Large investors have recently modified their holdings of the business. Royal Bank of Canada grew its stake in shares of Privia Health Group by 63.5% in the first quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock worth $5,514,000 after purchasing an additional 95,371 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Privia Health Group by 24.7% during the 1st quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock worth $916,000 after buying an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Privia Health Group by 3.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock valued at $2,666,000 after buying an additional 3,714 shares during the last quarter. Intech Investment Management LLC increased its stake in shares of Privia Health Group by 55.1% in the first quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock valued at $1,270,000 after buying an additional 20,082 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of Privia Health Group in the first quarter valued at about $154,000. Institutional investors own 94.48% of the company’s stock.

Wall Street Analyst Weigh In

PRVA has been the subject of several research analyst reports. Citigroup lowered their target price on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. BMO Capital Markets started coverage on shares of Privia Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price objective for the company. Barclays raised their target price on shares of Privia Health Group from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Piper Sandler reiterated an “overweight” rating and set a $36.00 price target on shares of Privia Health Group in a report on Thursday, February 26th. Finally, Truist Financial increased their price target on Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.